ATE530640T1 - Integrin-bindungsdomäne der map-kinase - Google Patents
Integrin-bindungsdomäne der map-kinaseInfo
- Publication number
- ATE530640T1 ATE530640T1 AT01271913T AT01271913T ATE530640T1 AT E530640 T1 ATE530640 T1 AT E530640T1 AT 01271913 T AT01271913 T AT 01271913T AT 01271913 T AT01271913 T AT 01271913T AT E530640 T1 ATE530640 T1 AT E530640T1
- Authority
- AT
- Austria
- Prior art keywords
- map kinase
- binding domain
- integrin
- integrin binding
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR2305A AUPR230500A0 (en) | 2000-12-22 | 2000-12-22 | A method of modulating map kinase mediated cellular activity and agents useful in same |
PCT/AU2001/001672 WO2002051993A1 (en) | 2000-12-22 | 2001-12-21 | MAP kinase integrin-binding domain |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE530640T1 true ATE530640T1 (de) | 2011-11-15 |
Family
ID=3826339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01271913T ATE530640T1 (de) | 2000-12-22 | 2001-12-21 | Integrin-bindungsdomäne der map-kinase |
Country Status (5)
Country | Link |
---|---|
US (1) | US7422883B2 (de) |
EP (1) | EP1352055B1 (de) |
AT (1) | ATE530640T1 (de) |
AU (1) | AUPR230500A0 (de) |
WO (1) | WO2002051993A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004281077B2 (en) * | 2003-10-17 | 2010-12-02 | Inter-K Pty Limited | Methods and agents for the treatment of cancer |
EP1805210A4 (de) | 2004-09-09 | 2007-10-24 | Auckland Uniservices Ltd | Neue peptide und verfahren zur behandlungvon entzündungskrankheiten |
US8080252B2 (en) * | 2006-07-19 | 2011-12-20 | The Cleveland Clinic Foundation | Compounds and methods of modulating angiogenesis |
ES2662036T3 (es) * | 2007-02-28 | 2018-04-05 | Yeda Research And Development Company Limited | Secuencias que se dirigen al núcleo |
DK2126064T3 (da) | 2007-03-27 | 2012-09-10 | Intrexon Corp | MEK-ligander og polynukleotider til kodning af MEK-ligander |
WO2009103127A1 (en) * | 2008-02-22 | 2009-08-27 | Inter-K Pty Limited | Therapeutic peptides |
JP2012518602A (ja) * | 2009-02-23 | 2012-08-16 | インター−ケイ ピーティーワイ リミテッド | 複数の細胞活性化経路の阻害 |
EP2807180B1 (de) | 2012-01-24 | 2018-03-28 | InterK Peptide Therapeutics Limited | Peptidmittel zur krebstherapie |
WO2015040609A1 (en) | 2013-09-17 | 2015-03-26 | Yeda Research And Development Co. Ltd. | Erk-derived peptides and uses thereof |
WO2020107079A1 (en) * | 2018-11-30 | 2020-06-04 | Interk Peptide Therapeutics Limited | Polypeptides and methods for improving skin conditions |
US20200319174A1 (en) * | 2019-04-17 | 2020-10-08 | Jiangnan University | Method for Detecting Human Soluble Asialoglycoprotein Receptor |
CN116041482B (zh) * | 2022-09-29 | 2024-05-03 | 江汉大学 | 一种结构肽段的cDNA、结构肽段和制备方法及应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE911869A1 (en) | 1990-06-01 | 1991-12-04 | Regeneron Pharma | A family of map2 protein kinases |
WO1992012236A1 (en) | 1991-01-11 | 1992-07-23 | The Regents Of The University Of California | A NOVEL INTEGRIN β SUBUNIT AND USES THEREOF |
US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
US6514745B1 (en) | 1993-07-19 | 2003-02-04 | The Regents Of The University Of California | Oncoprotein protein kinase |
US6495518B1 (en) | 1994-06-13 | 2002-12-17 | Vanderbilt University | Method for importing biologically active molecules into cells |
US5807746A (en) | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
WO1998016241A1 (en) | 1996-10-15 | 1998-04-23 | Vanderbilt University | Method of disrupting cellular adhesion |
US6007991A (en) | 1997-03-28 | 1999-12-28 | The Research Foundation Of Suny | Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer |
PT1504764E (pt) | 1997-08-08 | 2009-01-14 | Univ California | Tratamento da fibrose hepática com anticorpos contra integrina alfa-v-beta 6 |
US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
ATE385503T1 (de) | 1999-06-28 | 2008-02-15 | Inter K Pty Ltd | Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien |
US6312956B1 (en) | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
WO2001097827A1 (en) | 2000-06-16 | 2001-12-27 | Argonex Pharmaceuticals | Mhc peptides over-expressed on prostate cancer cells and methods of use |
-
2000
- 2000-12-22 AU AUPR2305A patent/AUPR230500A0/en not_active Abandoned
-
2001
- 2001-12-21 US US10/451,291 patent/US7422883B2/en not_active Expired - Fee Related
- 2001-12-21 AT AT01271913T patent/ATE530640T1/de not_active IP Right Cessation
- 2001-12-21 EP EP01271913A patent/EP1352055B1/de not_active Expired - Lifetime
- 2001-12-21 WO PCT/AU2001/001672 patent/WO2002051993A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AUPR230500A0 (en) | 2001-01-25 |
US20050214755A1 (en) | 2005-09-29 |
EP1352055A4 (de) | 2004-07-07 |
US7422883B2 (en) | 2008-09-09 |
EP1352055A1 (de) | 2003-10-15 |
WO2002051993A1 (en) | 2002-07-04 |
EP1352055B1 (de) | 2011-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE530640T1 (de) | Integrin-bindungsdomäne der map-kinase | |
BR9811956A (pt) | Naftiridinonas para a inibição de proteìna tirosina cinase e de proliferação celular mediada por cinase de ciclo de célula | |
MXPA00004256A (es) | Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor. | |
NO2010002I2 (no) | Toceranibfosfat. | |
DK0986382T3 (da) | RAF-kinasehæmmere | |
NO985574L (no) | FremgangsmÕter og preparater anvendelige for inhibering av angiogenese | |
AR023777A1 (es) | Nuevos compuestos | |
DE60238058D1 (de) | Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau | |
EE200000033A (et) | Uudsed tetrasoolderivaadid | |
EP1231914A4 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
ATE257152T1 (de) | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia | |
UA66793C2 (uk) | Лептин як стримувач швидкого збільшення пухлини клітини | |
CY1105048T1 (el) | Αγγελιαφορο pca3 ειδος rna σε καλοηθεις και κακοηθεις ιστους προστατη | |
DK1109810T3 (da) | Benzonaphthydin-N-oxider med PDE3- og PDE4-inhiberende aktivitet | |
DE60029318D1 (de) | Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen | |
DE60030164D1 (de) | 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie | |
DE60002855D1 (de) | Haloalkoxy-imidazonaphthyridine | |
BR0108391A (pt) | Citocinas modificadas para o uso em terapia de câncer | |
ATE356810T1 (de) | Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung | |
PT1147103E (pt) | Fenantridina-n-oxidos com actividade inibitoria de pde-iv | |
ATE233483T1 (de) | Wässrige lösung zum konservieren von gewebe und organen | |
PT1147088E (pt) | 6-arilfenantridinas com actividade inibitoria da pde-iv | |
WO2001042792A3 (en) | Diagnosis of cervical cancer using marker proteins | |
EP1196449A4 (de) | VERFAHREN ZUR MODULIERUNG VON INTEGRIN-VERMITTELTER ZELLAKTIVITäT UND HIERFüR GEEIGNETE REAGENZIEN | |
DE60229414D1 (de) | Verwendung von aplidine in der behandlung von pankreaskrebs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |